Abstract
Purpose of Review
Patients with inflammatory bowel disease (IBD) are not receiving preventative care services at the same rate as the general population. IBD patients are at increased risk for infections, osteoporosis, and certain malignancies secondary to their disease and as they are on immunosuppressive therapy. They are a younger population and often times consider their gastroenterologist as their primary care physician. In this review, we discuss up-to-date evidence pertaining to vaccine-preventable illnesses in the immunosuppressed IBD patient, screening for bone health, cervical cancer, skin malignancies, psychological wellbeing, and smoking cessation.
Recent Findings
Vaccinations are recommended in the IBD population as they are immunosuppressed and at increased risk for acquiring influenza and pneumonia. Not only are they at greater risk to acquire it but they also have a much severe complicated course. Ideally, IBD patients should be vaccinated prior to initiating immunosuppression and most inactive vaccines can be administered to them while they are on therapy. All IBD patients should be encouraged to stop smoking and have adequate vitamin D intake along with appropriate applicable cancer screenings.
Summary
Gastroenterologists must work in collaboration with primary care providers along with other specialists to help provide our patients well-rounded care for their IBD.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152(2):313–321 e2.
• Selby L, Kane S, Wilson J, Balla P, Riff B, Bingcang C, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008; 14(2):253–8. The first article published before the widespread use of biologics for IBD to address an issue that had not been recognized previously.
Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15(9):1399–409.
Desalermos AP, Farraye FA, Wasan SK. Vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2015;9(1):91–102.
Reich J, Wasan S, Farraye FA. Vaccinating patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016; 12(9):540–546.
Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105(6):1231–8.
Malhi G, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis. 2015;9(6):439–44.
Melmed GY. Immunizations and IBD: whose responsibility is it? If I’m the prescribing doctor, shouldn’t it be mine? Inflamm Bowel Dis. 2012;18(1):41–2.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18.
Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(5):677–92.
• Long MD, Gulati A, Wohl D, Herfarth H. Immunizations in pediatric and adult patients with inflammatory bowel disease: a practical case-based approach. Inflamm Bowel Dis. 2015;21(8):1993–2003. A practical clinically relevant article that can help clinicians at the bedside decide what vaccines are appropriate for their patients
Stobaugh DJ, Deepak P, Ehrenpreis ED. Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol. 2013;6:43–9.
Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. Influenza Other Respir Viruses. 2013;7(Suppl 2):72–5.
Andrisani G, Frasca D, Romero M, Armuzzi A, Felice C, Marzo M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: effects of combined therapy with immunosuppressants. J Crohns Colitis. 2013;7(4):301–7.
Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67(5):713–6.
Hagihara Y, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis. 2014;8(3):223–33.
Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009;104(2):444–53.
Melmed GY. Vaccinations while on thiopurines: some protection is better than none. Am J Gastroenterol. 2012;107(1):141–2.
Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(2):240–8.
Kim DK, Bridges CB, Harriman KH, Advisory Committee on Immunization P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med 2016; 164(3):184–194.
de Bruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia MF, Ueno A, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638–47.
Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60(4):456–62.
Reich JS, Miller HL, Wasan SK, Noronha A, Ardagna E, Sullivan K, et al. Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2015;11(6):396–401.
Cohen JI. A new vaccine to prevent herpes zoster. N Engl J Med. 2015;372(22):2149–50.
Marin AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11273–81.
• Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017; 112(2):241–58. An up-to-date evidence-based guideline for all of the issues mentioned in this article.
Jiang HY, Wang SY, Deng M, Li YC, Ling ZX, Shao L, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine. 2017;35(20):2633–41.
Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(8):797–813.
Bernstein CN. Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4(2):152–156.
Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122(7):599–604.
Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93(9):1483–90.
Shen B, Remzi FH, Oikonomou IK, Lu H, Lashner BA, Hammel JP, et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol. 2009;104(3):639–46.
Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62(2):105–8.
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.
van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105–11.
Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000.
Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631–6.
Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(8):1158–60.
Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136(2):451–8.
Sinclair JA, Wasan SK, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin N Am. 2012;41(2):325–37.
Committee on Practice B-G. Practice bulletin no. 168: cervical cancer screening and prevention. Obstet Gynecol. 2016;128(4):e111–30.
Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22(3):752–62.
Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejon A, et al. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis. 2006;12(8):692–6.
Ananthakrishnan AN, Gainer VS, Cai T, Perez RG, Cheng SC, Savova G, et al. Similar risk of depression and anxiety following surgery or hospitalization for Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2013;108(4):594–601.
Smithson S, Pignone MP. Screening adults for depression in primary care. Med Clin North Am. 2017;101(4):807–21.
Deter HC, Keller W, von Wietersheim J, Jantschek G, Duchmann R, Zeitz M, et al. Psychological treatment may reduce the need for healthcare in patients with Crohn’s disease. Inflamm Bowel Dis. 2007;13(6):745–52.
Mahid SS, Minor KS, Stevens PL, Galandiuk S. The role of smoking in Crohn’s disease as defined by clinical variables. Dig Dis Sci. 2007;52(11):2897–903.
Odes HS, Fich A, Reif S, Halak A, Lavy A, Keter D, et al. Effects of current cigarette smoking on clinical course of Crohn’s disease and ulcerative colitis. Dig Dis Sci. 2001;46(8):1717–21.
Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107(9):1399–406.
Severs M, van Erp SJ, van der Valk ME, Mangen MJ, Fidder HH, van der Have M, et al. Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(4):455–61.
Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41(1):1–9.
Nunes T, Etchevers MJ, Merino O, Gallego S, Garcia-Sanchez V, Marin-Jimenez I, et al. Does smoking influence Crohn’s disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis. 2013;19(1):23–9.
Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C. Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn’s disease. Aliment Pharmacol Ther. 2013;37(4):430–7.
Cosnes J. Smoking and diet: impact on disease course? Dig Dis. 2016;34(1–2):72–7.
Nunes T, Etchevers MJ, Domenech E, Garcia-Sanchez V, Ber Y, Penalva M, et al. Smoking does influence disease behaviour and impacts the need for therapy in Crohn’s disease in the biologic era. Aliment Pharmacol Ther. 2013;38(7):752–60.
Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20(1):213–27.
Moran GW, Lim AW, Bailey JL, Dubeau MF, Leung Y, Devlin SM, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(9):1002–24.
Sifuentes H, Kane S. Monitoring for extra-intestinal cancers in IBD. Curr Gastroenterol Rep 2015; 17 (11):42.
Nissen LHC, Pierik M, Derikx L, de Jong E, Kievit W, van den Heuvel TRA, et al. Risk factors and clinical outcomes in patients with IBD with melanoma. Inflamm Bowel Dis. 2017;23:2018–26.
Beaugerie L. Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented? Dig Dis. 2012;30(4):415–9.
Reasons Reported by Medicare Beneficiaries for Not Receiving Influenza and Pneumococcal Vaccinations -- United States, 1996. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4839a4.htm. Accessed 2 Oct, 2017.
Pneumococcal Vaccine Recommendations | Vaccines and Immunizations | CDC. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html. Accessed 2 Oct 2017.
ACIP Pneumococcal Vaccine Recommendations | CDC. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html. Accessed 2 Oct 2017.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Sunanda Kane reports working as a consultant to AbbVie, Janssen, and Seres and received research funding from UCB. Fazia Mir declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of Topical Collection on Inflammatory Bowel Diseases
Rights and permissions
About this article
Cite this article
Mir, F.A., Kane, S.V. Health Maintenance in Inflammatory Bowel Disease. Curr Gastroenterol Rep 20, 23 (2018). https://doi.org/10.1007/s11894-018-0621-1
Published:
DOI: https://doi.org/10.1007/s11894-018-0621-1